<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150830023823N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-01-13</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of topical Anethum graveolens Linn. seed (dill) oil on mild and moderate carpal tunnel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of topical Anethum graveolens Linn. seed (dill) oil on mild and moderate carpal tunnel syndrome a randomized, double-blind, placebo-controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>112</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87694</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we use permutation block randomization method with blocks of size 4 and an allocation ratio of 1:1.Therefore, according to the sample size (112 subjects), 28 blocks of size 4 can be considered. For this purpose, since we have two interventions, we initially will name them A and B. Then by using Random Allocation Software 2.0, we generate a list of 112 random sequences. Finally, based on this random list, 56 patients will be allocated to group A and 56 patients to group B, Blinding description: The placebo will be made in color, odor, package and other characteristics similar to dill seed oil so that the patients and the researchers can`t distinguish between them.</study_design>
      <phase>3</phase>
      <hc_freetext>Carpal tunnel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in intervention group use a wrist splint as standard treatment, every night and during sleep for 4 weeks. In addition, the topical dill seed oil as the test drug is applied twice a day (morning and evening) for 4 weeks to 5 drops per use on the palm and wrist area, 2-3 cm above and below wrist crease of the affected hand/hands, without massage. Also, patients receive two blister of 325 mg acetaminophen tablets as rescue analgesic to take PRN in case of pain due to CTS. Intervention 2: Control group: Patients in control group use a wrist splint as standard treatment, every night and during sleep for 4 weeks. In addition, the topical placebo oil is applied twice a day (morning and evening) for 4 weeks to 5 drops per use on the palm and wrist area, 2-3 cm above and below wrist crease of the affected hand/hands, without massage. Also, patients receive two blister of 325 mg acetaminophen tablets as rescue analgesic to take PRN in case of pain due to CTS.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is for privacy</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Tavakoli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St، Medical School، Seventh floor، Persian Medicine Department</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 712345145</telephone>
        <email>tavakkolia@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Tavakoli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St، School of Medicine، Seventh floor، Persian Medicine Department</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 712345145</telephone>
        <email>tavakkolia@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1-Clinical diagnosis of mild to moderate idiopathic carpal tunnel syndrome by an orthopedic specialist based on history and physical examination as at least 2 symptoms or 1 symptom plus 1 sign (symptoms include: pain, paresthesia, hypoesthesia, numbness and tingling,  and signs include: positive Phalen test or Tinel test)
2-Electrodiagnostic evidence of mild to moderate idiopathic carpal tunnel syndrome which includes the following : •	SDL &gt; 3/7 m/s2c•	SNCV &lt; 40 m/sec•	 MDL &gt; 4/2 m/sec•	CL &gt; 2/4 m/sec
3-Voluntary acceptance of the terms of participation in the study and sign the informed consent form</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Inability tto fill out  the questionnaire.
History of sensitivity to dill seed oil
Severe idiopathic carpal tunnel syndrome based on electrodiagnostic tests
History of severe trauma or fracture of the wrist bones or surgery or injection into the carpal tunnel  during the past 6 months
Thenar muscle atrophy
Rheumatological diseases such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and amyloidosis
Pregnant or lactating women
Diabetes or hypothyroidism
Recent or ongoing inevitable use of corticosteroids or analgesics
Coexisting serious illness, such as renal and heart failure
life-threatening diseases such as advanced cancer
Diseases that can mimic carpal tunnel syndrome, such as multiple sclerosis
Use of anticancer drugs and corticosteroids
Clinical and electrodiagnostic signs of polyneuropathy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in intervention group use a wrist splint as standard treatment, every night and during sleep for 4 weeks. In addition, the topical dill seed oil as the test drug is applied twice a day (morning and evening) for 4 weeks to 5 drops per use on the palm and wrist area, 2-3 cm above and below wrist crease of the affected hand/hands, without massage. Also, patients receive two blister of 325 mg acetaminophen tablets as rescue analgesic to take PRN in case of pain due to CTS.</i_keyword>
      <i_keyword>Control group: Patients in control group use a wrist splint as standard treatment, every night and during sleep for 4 weeks. In addition, the topical placebo oil is applied twice a day (morning and evening) for 4 weeks to 5 drops per use on the palm and wrist area, 2-3 cm above and below wrist crease of the affected hand/hands, without massage. Also, patients receive two blister of 325 mg acetaminophen tablets as rescue analgesic to take PRN in case of pain due to CTS.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of disease (symptoms and functional status). Timepoint: At the beginning of the enrollment to the study and after 4 weeks of intervention. Method of measurement: Boston Questionnaire (BCTQ).</prim_outcome>
      <prim_outcome>Electrodiagnostic indices of the median nerve. Timepoint: At the beginning of the enrollment to the study and after 4 weeks of intervention. Method of measurement: Electromyography device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Local side effect. Timepoint: Daily. Method of measurement: Adverse Drug Reaction Reporting Form.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-26</approval_date>
        <contact_name>Ethics Committee of Shiraz Medical School</contact_name>
        <contact_address>Zand St. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
